Molecular Orbital Calculations on Tumour-Inhibitory Phenyl Aziridines: Qsars

References

• von Ardenne M., Rieger F. Mathematical in vivo theory of tumour formation. Zeitschrift fur Noturforschung 1966; 21B: 472–482
   Google Scholar
• Bak B., Skaarup S. The substitution structure of ethyleneimine. Journal of Molecular Structure 1971; 3: 55–198
   Google Scholar
• Bingham R. C., Dewar M. J. S., Lo D. H. Ground states of molecules XXV. MINDO/3: An improved version of the MINDO semi‐empirical SCF‐MO method. Journal of the American Chemical Society 1975; 97: 1285–1293
   Web of Science ®Google Scholar
• Burke J. F., Whitehouse M. W. Concerning the differences in uncoupling activity of isomeric dinitrophenols. Biochemical Pharmacology 1967; 16: 209–211
   Google Scholar
• Cammarata A. Quantum perturbation theory and linear free energy relationships in the study of drug action. Molecular Orbital Studies of Chemical Pharmacology, L. B. Kier. Springer‐Verlag, New York 1970; 156–190
   Google Scholar
• Carsten M. E., Eisen H. N. The interaction of dinitrobenzene derivatives with bovine serum albumin. Journal of the American Chemical Society 1953; 75: 4451–4456
   Google Scholar
• Clark D. T. Non empirical LCAO‐MO‐SCF calculations with Gaussian type functions on some three membered ring heterocycles. Theoretica Chimica Acta 1969; 15: 225–234
   Google Scholar
• Cobb L. M., Connors T. A., Elson L. A., Khan A. M., Mitchley B. C. V., Ross W. C. J., Whisson M. E. 2,4‐Dinitro‐5‐ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochemical Pharmacology 1969; 18: 1519–1527
   PubMed Web of Science ®Google Scholar
• Connors T. A., Hickman J. A., Jarman M., Melzack D. H., Ross W. C. J. The metabolism of the anti‐tumour agent 1(1‐aziridinyl)‐2,4‐dinitrobenzene (CB 1937). Biochemical Pharmacology 1973; 24: 1665–1670
   Google Scholar
• Connors T. A., Mandel H. G., Melzack D. H. Studies on the reversal of the selective anti‐tumour effect of the aziridinyl derivative CB 1954 by 4‐amino‐5‐imidazole carboxamide. International Journal of Cancer 1972; 9: 126–132
   Google Scholar
• Connors T. A., Melzack D. M. Studies on the mechanism of action of 5‐aziridinyl‐2,4‐dinitrobenzamide (CB 1954), a selective inhibitor of the Walker tumour. International Journal of Cancer 1971; 7: 86–92
   Google Scholar
• Dermer O. C., Ham G. E. Ethylenimine and Other Aziridines. Academic Press, New York 1969
   Google Scholar
• Eden M., Haines B., Kahler H. The pH of rat tumours measured in vivo. Journal of the National Cancer Institute 1955; 16: 541–556
   PubMedGoogle Scholar
• Emmelot P. The molecular basis of cancer chemotherapy. Molecular Pharmacology, E. J. Ariens. Academic Press, New York 1964; Vol. 2: 55–198
   Google Scholar
• Hickman J. A. Structure activity relationships in a series of anti‐neoplastic dinitrophenyl aziridines—protein binding studies. Biochemical Pharmacology 1974; 23: 2833–2838
   Google Scholar
• Iball J., Scrimgeour S. N., Williams B. C. The crystal and molecular structure of 2,4‐dinitro‐5‐ethyleneiminobenzamide. Acta Crystallographia 1975; B31: 1121–1123
   Google Scholar
• Jarman M., Melzack D. H., Ross W. C. J. The metabolism of the anti‐tumour agent 5(1‐aziridinyl)2,4‐dinitrobenzamide. Biochemical Pharmacology 1976; 25: 2475–2478
   Google Scholar
• Khan A. H., Ross W. C. J. Tumour‐growth inhibitory nitrophenyl aziridines and related compounds: structure‐activity relationship. Chemical‐Biological Interactions 1970; 1: 27–47
   Google Scholar
• Khan A. H., Ross W. C. J. Tumour‐growth inhibitory nitrophenyl aziridines and related compounds: structure‐activity relationships. Chemical‐Biological Interactions 1972; 4: 11–22
   Google Scholar
• Lehn J. M., Munsch B., Millie P., Veillard A. Theoretical conformational analysis III. Nitrogen inversion: An ab initio SCF‐LCAO‐MO study of aziridine and oxaziridine. Theoretica Chimica Acta 1969; 13: 313–339
   Google Scholar
• Mandel H. G., Connors T. A., Melzack D. H., Merai K. Studies on the mechanism of action of 5‐aziridinyl‐2,4‐dinitrobenzamide in tumours cells. Cancer Research 1974; 34: 275–280
   Google Scholar
• Morokuma H., Fukui K., Kato H. The electronic structures and antioxidizing activities of substituted phenols. Bulletin of the Chemical Society of Japan 1963; 36: 541–546
   Web of Science ®Google Scholar
• Ross W. C. J. The chemistry of cytotoxic alkylating agents. Cancer Research 1953; 1: 397–449
   PubMed Web of Science ®Google Scholar
• Schloerb P. R., Blackburn G. L., Grantham J. J., Mallard D. S., Cage G. K. Intracellular pH and buffering capacity of the Walker‐256 carcinoma. Surgery 1965; 58: 5–11
   Google Scholar
• Shapot V. S. Some biochemical aspects of the relationship between the tumour and the host. Advances in Cancer Research 1972; 15: 253–286
   Google Scholar
• Stock J. A. Design of tumour‐inhibitory alkylating drugs. Drug Design, E. J. Ariens. Academic Press, New York 1971; Vol. 2: 532–571
   Google Scholar
• Sutton L. E. Tables of interatomic distances and configurations in molecules and ions. Chemical Society Special Publication 1958; 1: 1, London
   Google Scholar
• Tisdale M. J. Alkylating analogues of the tumour inhibitor 5‐aziridino 2,4‐dinitrobenzamide. Chemico‐Biological Interactions 1971; 3: 95–107
   Google Scholar
• Yates K., Stevens J. B. The ionization behaviour of amides in concentrated sulphuric acids. Canadian Journal of Chemistry 1965; 43: 529–537
   Google Scholar